Connect Biopharma (CNTB) Expected to Announce Earnings on Monday

Connect Biopharma (NASDAQ:CNTB) is expected to post its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Connect Biopharma to post earnings of ($0.30) per share and revenue of $0.0010 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 9:30 AM ET.

Connect Biopharma Trading Down 3.8%

Shares of NASDAQ CNTB opened at $2.76 on Monday. Connect Biopharma has a twelve month low of $0.51 and a twelve month high of $3.28. The firm has a market cap of $154.28 million, a PE ratio of -3.78 and a beta of -0.20. The business has a fifty day simple moving average of $2.56 and a two-hundred day simple moving average of $2.24. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.01.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in CNTB. Perceptive Advisors LLC purchased a new stake in shares of Connect Biopharma during the 4th quarter worth $2,235,000. Knott David M Jr purchased a new position in Connect Biopharma in the fourth quarter valued at about $564,000. Marshall Wace LLP raised its holdings in Connect Biopharma by 121.2% in the fourth quarter. Marshall Wace LLP now owns 128,368 shares of the company’s stock worth $362,000 after purchasing an additional 70,337 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Connect Biopharma during the fourth quarter valued at about $232,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of Connect Biopharma during the fourth quarter valued at about $228,000. 58.72% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on CNTB. Lake Street Capital started coverage on Connect Biopharma in a research note on Monday, December 1st. They set a “buy” rating and a $9.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Connect Biopharma in a report on Wednesday, January 21st. Finally, Wall Street Zen raised shares of Connect Biopharma to a “hold” rating in a research report on Saturday, December 20th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.67.

Connect Biopharma Company Profile

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.